Ravulizumab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial
New England Journal of Medicine · 12.11.2026 · 395 (19) · 1921-1931
DOI: 10.1056/nejmoa2607544 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 12.11.2026. Verfasst von Jonathan Barratt und 24 weiteren Autor:innen. Beteiligte Einrichtung: University of Leicester, Leicester, United Kingdom. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Complement Inactivating Agents, Glomerulonephritis, IGA, Proteinuria. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Alexion, AstraZeneca Rare Disease.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Leicester, Leicester, United Kingdom.
- Clinical Development, Alexion, AstraZeneca Rare Disease, Boston.
- Biostatistics, Alexion, AstraZeneca Rare Disease, Boston.
- Translational Biomarker Research, Alexion, AstraZeneca Rare Disease, New Haven, CT.
- Tufts Medical Center, Boston.
- Nephrology Service, Hospital Británico de Buenos Aires, Buenos Aires.
ORCID-Profile: Hiddo J L Heerspink
Förderung
- Alexion, AstraZeneca Rare Disease
Zitieren
APA
Barratt, J., Farag, Y. M. K., Rice, K., Cammett, T. J., Inker, L. A., Trimarchi, H., Bruchfeld, A., Heerspink, H. J. L., Liew, A., Carroll, K., Zhang, H., Norouzi, S., Hou, S., Park, S., Pérez Valdivia, M. Á., Radhakrishnan, J., Suzuki, Y., Schneider, B., Marsala, J., …, & I CAN Trial Group (2026). Ravulizumab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial. New England Journal of Medicine, 395(19), 1921-1931. https://doi.org/10.1056/nejmoa2607544
Vancouver
Barratt J, Farag YMK, Rice K, Cammett TJ, Inker LA, Trimarchi H, et al. Ravulizumab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial. New England Journal of Medicine. 2026;395(19):1921-1931. doi:10.1056/nejmoa2607544
BibTeX
@article{Barratt2026,
author = {Barratt, Jonathan and Farag, Youssef M K and Rice, Kara and Cammett, Tobin J and Inker, Lesley A and Trimarchi, Hernán and Bruchfeld, Annette and Heerspink, Hiddo J L and Liew, Adrian and Carroll, Kevin and Zhang, Hong and Norouzi, Sayna and Hou, Shuang and Park, Sehoon and Pérez Valdivia, Miguel Ángel and Radhakrishnan, Jai and Suzuki, Yusuke and Schneider, Bonnie and Marsala, John and Carrillo-Infante, Cynthia and Lake, Stephen L and Singh, Ajay K and Nolan, Stephen and Lafayette, Richard A and I CAN Trial Group, I CAN Trial Group},
title = {Ravulizumab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial},
journal = {New England Journal of Medicine},
year = {2026},
volume = {395},
number = {19},
pages = {1921--1931},
doi = {10.1056/nejmoa2607544}
}
EUVIMED